Detalles de la búsqueda
1.
Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
Haemophilia
; 30(2): 388-394, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38229269
2.
Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.
Acta Haematol
; : 1-10, 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38599195
3.
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A.
Haemophilia
; 29(4): 1032-1038, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37252898
4.
Factors associated with physical activity in young people with haemophilia A on prophylaxis.
Haemophilia
; 29(3): 900-909, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36913380
5.
Physical activity in Norwegian teenagers and young adults with haemophilia A compared to general population peers.
Haemophilia
; 29(2): 658-667, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36723510
6.
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - A modified Delphi consensus by the ADVANCE Working Group.
Haemophilia
; 29(1): 21-32, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36271497
7.
Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: A cohort study.
J Stroke Cerebrovasc Dis
; 32(1): 106860, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36403363
8.
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
Haemophilia
; 28(5): 713-719, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35575446
9.
Bone mineral density in haemophilia - a multicentre study evaluating the impact of different replacement regimens.
Haemophilia
; 28(2): 239-246, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34994489
10.
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81-8973.
Haemophilia
; 28(2): 223-229, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35005818
11.
Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
Haemophilia
; 28(2): 215-222, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34918839
12.
Comparison of free-living physical activity measurements between ActiGraph GT3X-BT and Fitbit Charge 3 in young people with haemophilia.
Haemophilia
; 28(6): e172-e180, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35830613
13.
Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology.
Platelets
; 33(4): 640-644, 2022 May 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35225150
14.
Management of comorbidities in haemophilia.
Haemophilia
; 27 Suppl 3: 37-45, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32476243
15.
Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery.
Haemophilia
; 27(4): 519-530, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33988293
16.
Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study.
Haemophilia
; 27(3): e347-e356, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33818853
17.
Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study.
Br J Haematol
; 191(3): 460-465, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32342497
18.
The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis.
Platelets
; 31(1): 43-47, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-30569801
19.
Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries.
Haemophilia
; 25(1): 54-59, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30394617
20.
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results.
Haemophilia
; 25(6): 1011-1019, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31621991